Nucleic Acid Therapeutics

Papers
(The H4-Index of Nucleic Acid Therapeutics is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study102
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Tr66
Delivery of RNA Therapeutics: The Great Endosomal Escape!56
Transcriptome-Wide Off-Target Effects of Steric-Blocking Oligonucleotides51
Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives49
Challenges and Opportunities for Nucleic Acid Therapeutics34
Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs33
Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics30
Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer29
Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features27
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides25
Researcher's Perceptions on Publishing “Negative” Results and Open Access23
miR-21: A Key Small Molecule with Great Effects in Combination Cancer Therapy21
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides20
Antisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes20
Quantification of Antisense Oligonucleotides by Splint Ligation and Quantitative Polymerase Chain Reaction18
Mesyl Phosphoramidate Oligonucleotides as Potential Splice-Switching Agents: Impact of Backbone Structure on Activity and Intracellular Localization18
Human Papillomavirus G-Rich Regions as Potential Antiviral Drug Targets17
Assay, Purity, and Impurity Profile of Phosphorothioate Oligonucleotide Therapeutics by Ion Pair–HPLC–MS17
0.038177967071533